Cargando…

Multiomics Analysis of Plasma Proteomics and Metabolomics of Steroid Resistance in Childhood Nephrotic Syndrome Using a “Patient-Specific” Approach

INTRODUCTION: Nephrotic syndrome (NS) occurs commonly in children with glomerular disease and glucocorticoids (GCs) are the mainstay treatment. Steroid resistant NS (SRNS) develops in 15% to 20% of children, increasing the risk of chronic kidney disease compared to steroid sensitive NS (SSNS). NS pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhayana, Sagar, Zhao, Yue, Merchant, Michael, Cummins, Timothy, Dougherty, Julie A., Kamigaki, Yu, Pathmasiri, Wimal, McRitchie, Susan, Mariani, Laura H., Sumner, Susan, Klein, Jon B., Li, Lang, Smoyer, William E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10239920/
https://www.ncbi.nlm.nih.gov/pubmed/37284673
http://dx.doi.org/10.1016/j.ekir.2023.03.015
_version_ 1785053602910306304
author Bhayana, Sagar
Zhao, Yue
Merchant, Michael
Cummins, Timothy
Dougherty, Julie A.
Kamigaki, Yu
Pathmasiri, Wimal
McRitchie, Susan
Mariani, Laura H.
Sumner, Susan
Klein, Jon B.
Li, Lang
Smoyer, William E.
author_facet Bhayana, Sagar
Zhao, Yue
Merchant, Michael
Cummins, Timothy
Dougherty, Julie A.
Kamigaki, Yu
Pathmasiri, Wimal
McRitchie, Susan
Mariani, Laura H.
Sumner, Susan
Klein, Jon B.
Li, Lang
Smoyer, William E.
author_sort Bhayana, Sagar
collection PubMed
description INTRODUCTION: Nephrotic syndrome (NS) occurs commonly in children with glomerular disease and glucocorticoids (GCs) are the mainstay treatment. Steroid resistant NS (SRNS) develops in 15% to 20% of children, increasing the risk of chronic kidney disease compared to steroid sensitive NS (SSNS). NS pathogenesis is unclear in most children, and no biomarkers exist that predict the development of pediatric SRNS. METHODS: We studied a unique patient cohort with plasma specimens collected before GC treatment, yielding a disease-only sample not confounded by steroid-induced gene expression changes (SSNS n = 8; SRNS n = 7). A novel “patient-specific” bioinformatic approach merged paired pretreatment and posttreatment proteomic and metabolomic data and identified candidate SRNS biomarkers and altered molecular pathways in SRNS versus SSNS. RESULTS: Joint pathway analyses revealed perturbations in nicotinate or nicotinamide and butanoate metabolic pathways in patients with SRNS. Patients with SSNS had perturbations of lysine degradation, mucin type O-glycan biosynthesis, and glycolysis or gluconeogenesis pathways. Molecular analyses revealed frequent alteration of molecules within these pathways that had not been observed by separate proteomic and metabolomic studies. We observed upregulation of NAMPT, NMNAT1, and SETMAR in patients with SRNS, in contrast to upregulation of ALDH1B1, ACAT1, AASS, ENPP1, and pyruvate in patients with SSNS. Pyruvate regulation was the change seen in our previous analysis; all other targets were novel. Immunoblotting confirmed increased NAMPT expression in SRNS and increased ALDH1B1 and ACAT1 expression in SSNS, following GC treatment. CONCLUSION: These studies confirmed that a novel “patient-specific” bioinformatic approach can integrate disparate omics datasets and identify candidate SRNS biomarkers not observed by separate proteomic or metabolomic analysis.
format Online
Article
Text
id pubmed-10239920
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-102399202023-06-06 Multiomics Analysis of Plasma Proteomics and Metabolomics of Steroid Resistance in Childhood Nephrotic Syndrome Using a “Patient-Specific” Approach Bhayana, Sagar Zhao, Yue Merchant, Michael Cummins, Timothy Dougherty, Julie A. Kamigaki, Yu Pathmasiri, Wimal McRitchie, Susan Mariani, Laura H. Sumner, Susan Klein, Jon B. Li, Lang Smoyer, William E. Kidney Int Rep Translational Research INTRODUCTION: Nephrotic syndrome (NS) occurs commonly in children with glomerular disease and glucocorticoids (GCs) are the mainstay treatment. Steroid resistant NS (SRNS) develops in 15% to 20% of children, increasing the risk of chronic kidney disease compared to steroid sensitive NS (SSNS). NS pathogenesis is unclear in most children, and no biomarkers exist that predict the development of pediatric SRNS. METHODS: We studied a unique patient cohort with plasma specimens collected before GC treatment, yielding a disease-only sample not confounded by steroid-induced gene expression changes (SSNS n = 8; SRNS n = 7). A novel “patient-specific” bioinformatic approach merged paired pretreatment and posttreatment proteomic and metabolomic data and identified candidate SRNS biomarkers and altered molecular pathways in SRNS versus SSNS. RESULTS: Joint pathway analyses revealed perturbations in nicotinate or nicotinamide and butanoate metabolic pathways in patients with SRNS. Patients with SSNS had perturbations of lysine degradation, mucin type O-glycan biosynthesis, and glycolysis or gluconeogenesis pathways. Molecular analyses revealed frequent alteration of molecules within these pathways that had not been observed by separate proteomic and metabolomic studies. We observed upregulation of NAMPT, NMNAT1, and SETMAR in patients with SRNS, in contrast to upregulation of ALDH1B1, ACAT1, AASS, ENPP1, and pyruvate in patients with SSNS. Pyruvate regulation was the change seen in our previous analysis; all other targets were novel. Immunoblotting confirmed increased NAMPT expression in SRNS and increased ALDH1B1 and ACAT1 expression in SSNS, following GC treatment. CONCLUSION: These studies confirmed that a novel “patient-specific” bioinformatic approach can integrate disparate omics datasets and identify candidate SRNS biomarkers not observed by separate proteomic or metabolomic analysis. Elsevier 2023-03-23 /pmc/articles/PMC10239920/ /pubmed/37284673 http://dx.doi.org/10.1016/j.ekir.2023.03.015 Text en © 2023 International Society of Nephrology. Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Translational Research
Bhayana, Sagar
Zhao, Yue
Merchant, Michael
Cummins, Timothy
Dougherty, Julie A.
Kamigaki, Yu
Pathmasiri, Wimal
McRitchie, Susan
Mariani, Laura H.
Sumner, Susan
Klein, Jon B.
Li, Lang
Smoyer, William E.
Multiomics Analysis of Plasma Proteomics and Metabolomics of Steroid Resistance in Childhood Nephrotic Syndrome Using a “Patient-Specific” Approach
title Multiomics Analysis of Plasma Proteomics and Metabolomics of Steroid Resistance in Childhood Nephrotic Syndrome Using a “Patient-Specific” Approach
title_full Multiomics Analysis of Plasma Proteomics and Metabolomics of Steroid Resistance in Childhood Nephrotic Syndrome Using a “Patient-Specific” Approach
title_fullStr Multiomics Analysis of Plasma Proteomics and Metabolomics of Steroid Resistance in Childhood Nephrotic Syndrome Using a “Patient-Specific” Approach
title_full_unstemmed Multiomics Analysis of Plasma Proteomics and Metabolomics of Steroid Resistance in Childhood Nephrotic Syndrome Using a “Patient-Specific” Approach
title_short Multiomics Analysis of Plasma Proteomics and Metabolomics of Steroid Resistance in Childhood Nephrotic Syndrome Using a “Patient-Specific” Approach
title_sort multiomics analysis of plasma proteomics and metabolomics of steroid resistance in childhood nephrotic syndrome using a “patient-specific” approach
topic Translational Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10239920/
https://www.ncbi.nlm.nih.gov/pubmed/37284673
http://dx.doi.org/10.1016/j.ekir.2023.03.015
work_keys_str_mv AT bhayanasagar multiomicsanalysisofplasmaproteomicsandmetabolomicsofsteroidresistanceinchildhoodnephroticsyndromeusingapatientspecificapproach
AT zhaoyue multiomicsanalysisofplasmaproteomicsandmetabolomicsofsteroidresistanceinchildhoodnephroticsyndromeusingapatientspecificapproach
AT merchantmichael multiomicsanalysisofplasmaproteomicsandmetabolomicsofsteroidresistanceinchildhoodnephroticsyndromeusingapatientspecificapproach
AT cumminstimothy multiomicsanalysisofplasmaproteomicsandmetabolomicsofsteroidresistanceinchildhoodnephroticsyndromeusingapatientspecificapproach
AT doughertyjuliea multiomicsanalysisofplasmaproteomicsandmetabolomicsofsteroidresistanceinchildhoodnephroticsyndromeusingapatientspecificapproach
AT kamigakiyu multiomicsanalysisofplasmaproteomicsandmetabolomicsofsteroidresistanceinchildhoodnephroticsyndromeusingapatientspecificapproach
AT pathmasiriwimal multiomicsanalysisofplasmaproteomicsandmetabolomicsofsteroidresistanceinchildhoodnephroticsyndromeusingapatientspecificapproach
AT mcritchiesusan multiomicsanalysisofplasmaproteomicsandmetabolomicsofsteroidresistanceinchildhoodnephroticsyndromeusingapatientspecificapproach
AT marianilaurah multiomicsanalysisofplasmaproteomicsandmetabolomicsofsteroidresistanceinchildhoodnephroticsyndromeusingapatientspecificapproach
AT sumnersusan multiomicsanalysisofplasmaproteomicsandmetabolomicsofsteroidresistanceinchildhoodnephroticsyndromeusingapatientspecificapproach
AT kleinjonb multiomicsanalysisofplasmaproteomicsandmetabolomicsofsteroidresistanceinchildhoodnephroticsyndromeusingapatientspecificapproach
AT lilang multiomicsanalysisofplasmaproteomicsandmetabolomicsofsteroidresistanceinchildhoodnephroticsyndromeusingapatientspecificapproach
AT smoyerwilliame multiomicsanalysisofplasmaproteomicsandmetabolomicsofsteroidresistanceinchildhoodnephroticsyndromeusingapatientspecificapproach
AT multiomicsanalysisofplasmaproteomicsandmetabolomicsofsteroidresistanceinchildhoodnephroticsyndromeusingapatientspecificapproach